MedTrace Logo

Post Trial Access Program of TAK-577 for Von Willebrand Disease (VWD)

NCT06173024 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-09-03

No results posted yet for this study

Summary

The post-trial access program allows eligible participants to gain access to unlicensed treatment on compassionate grounds. Recombinant von Willebrand factor (rVWF) also known as TAK-577, is a medicine to help treat Von Willebrand Disease (VWD). This post-trial access program enables continued access to children and adults who are benefitting from treatment on study SHP677-304 (NCT03879135) study.

Conditions

  • Von Willebrand Disease (VWD)

Interventions

BIOLOGICAL

TAK-577

TAK-577 as IV injection at dose calculated based on the participant's body weight.

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06173024 on ClinicalTrials.gov